Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of 8 mg Aflibercept in Chinese Participants With Diabetic Macular Edema

NCT06422507 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06422507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06422507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of 8 mg Aflibercept in Chinese Participants With Diabetic Macular Edema
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
May 29, 2024
Completion date
March 25, 2026
Enrollment
333 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema